Thrombosis Research

Papers
(The H4-Index of Thrombosis Research is 43. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
Incidence of thrombotic complications in critically ill ICU patients with COVID-193229
Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy1538
Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis1205
The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management424
Severe COVID-19 infection associated with endothelial activation335
Thrombosis risk associated with COVID-19 infection. A scoping review283
Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levels275
Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID)187
The clinical implication of dynamic neutrophil to lymphocyte ratio and D-dimer in COVID-19: A retrospective study in Suzhou China179
Venous thromboembolism in patients with COVID-19: Systematic review and meta-analysis168
D-dimer level is associated with the severity of COVID-19144
Pulmonary embolism in patients with COVID-19: Time to change the paradigm of computed tomography143
Clinical and computed tomography characteristics of COVID-19 associated acute pulmonary embolism: A different phenotype of thrombotic disease?137
Thrombotic complications of patients admitted to intensive care with COVID-19 at a teaching hospital in the United Kingdom135
Mechanisms involved in the development of thrombocytopenia in patients with COVID-19116
Severe arterial thrombosis associated with Covid-19 infection113
Is COVID-19 associated thrombosis caused by overactivation of the complement cascade? A literature review104
Anticoagulation and bleeding risk in patients with COVID-1992
Antiphospholipid antibodies are not elevated in patients with severe COVID-19 pneumonia and venous thromboembolism91
Image-proven thromboembolism in patients with severe COVID-19 in a tertiary critical care unit in the United Kingdom91
Estrogen and thrombosis: A bench to bedside review88
Admission D-dimer levels, D-dimer trends, and outcomes in COVID-1979
Incidence of thrombotic complications and overall survival in hospitalized patients with COVID-19 in the second and first wave76
Pulmonary embolism in hospitalised patients with COVID-1973
The role of Neutrophil Extracellular Traps in Covid-19: Only an hypothesis or a potential new field of research?72
Spontaneous HIT syndrome: Knee replacement, infection, and parallels with vaccine-induced immune thrombotic thrombocytopenia71
Pulmonary embolism in COVID-19 patients: prevalence, predictors and clinical outcome70
Mechanisms of thrombosis and cardiovascular complications in COVID-1969
COVID-19 and cardiovascular consequences: Is the endothelial dysfunction the hardest challenge?68
Incidence of venous and arterial thromboembolic complications in COVID-19: A systematic review and meta-analysis68
ADAMTS13 activity, von Willebrand factor, factor VIII and D-dimers in COVID-19 inpatients64
Are antiphospholipid antibodies associated with thrombotic complications in critically ill COVID-19 patients?62
Venous and arterial thromboembolic events with immune checkpoint inhibitors: A systematic review55
A relative ADAMTS13 deficiency supports the presence of a secondary microangiopathy in COVID 1955
Venous thromboembolism in non-critically ill patients with COVID-19 infection55
COVID-19 and thrombotic microangiopathies52
Biomarkers for the prediction of venous thromboembolism in critically ill COVID-19 patients50
Hypotheses behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination48
Incidence of symptomatic venous thromboembolism following hospitalization for coronavirus disease 2019: Prospective results from a multi-center study47
Sustained inflammation, coagulation activation and elevated endothelin-1 levels without macrovascular dysfunction at 3 months after COVID-1946
Pulmonary embolism in a young pregnant woman with COVID-1944
Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies43
Measuring functional limitations after venous thromboembolism: Optimization of the Post-VTE Functional Status (PVFS) Scale43
Prevalence and characteristics of pulmonary embolism in 1042 COVID-19 patients with respiratory symptoms: A nested case-control study43
Drug-drug interactions with direct oral anticoagulants associated with adverse events in the real world: A systematic review43
D-dimer cut-off points and risk of venous thromboembolism in adult hospitalized patients with COVID-1943
0.17879295349121